according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

SECTION 1. IDENTIFICATION

Product name : CLADRIBINE 10MG TABLETS

Manufacturer or supplier's details

Company : EMD Serono, Inc.

One Technology Place MA-02370 Rockland United States of America

Responsible Department : e-mail: HealthcareSDS@emdgroup.com

Emergency telephone num: 800-424-9300 CHEMTREC (USA)

ber

+1-703-527-3887 CHEMTREC (International)

613-996-6666 CANUTEC (Canada)

24 Hours/day; 7 Days/week

Recommended use of the chemical and restrictions on use

Recommended use : Use restricted under TSCA to research and development or

as analytical reagent. Uses regulated under FDA or FIFRA are

not affected.

finished pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Acute toxicity (Oral) : Category 4

Germ cell mutagenicity : Category 2

Reproductive toxicity : Category 2

Specific target organ toxicity

- repeated exposure

Category 1

GHS label elements

Hazard pictograms





Signal word : Danger

Hazard statements : H302 Harmful if swallowed.

H341 Suspected of causing genetic defects.

H361fd Suspected of damaging fertility. Suspected of damaging

the unborn child.

H372 Causes damage to organs through prolonged or repeated

exposure.

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P202 Do not handle until all safety precautions have been read

and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

P280 Wear protective gloves/ protective clothing/ eye protection/

face protection.

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON

CENTER/ doctor if you feel unwell. Rinse mouth.

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste dis-

posal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Chemical nature : Mixture of organic compounds

Components

Chemical name	CAS-No.	Concentration (% w/w)
cladribine	4291-63-8	>= 1 - < 5
magnesium distearate	557-04-0	>= 1 - < 5

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : Move out of dangerous area.

Show this safety data sheet to the doctor in attendance.

Do not leave the victim unattended.

If inhaled : Move to fresh air.

If symptoms persist, call a physician.

In case of skin contact : Rinse with water.

Remove contaminated clothing. If symptoms persist, call a physician.

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

In case of eye contact : Flush eyes with water as a precaution.

Remove contact lenses. Protect unharmed eye.

Keep eye wide open while rinsing.

If eye irritation persists, consult a specialist.

If swallowed : Keep respiratory tract clear.

Do not give milk or alcoholic beverages.

Never give anything by mouth to an unconscious person.

If symptoms persist, call a physician.

Most important symptoms and effects, both acute and

delayed

Gastrointestinal discomfort

Headache Nausea

immune system effects Harmful if swallowed.

Suspected of causing genetic defects.

Suspected of damaging fertility. Suspected of damaging the

unborn child.

Causes damage to organs through prolonged or repeated

exposure.

Notes to physician : Treat symptomatically.

SECTION 5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water

Foam

Carbon dioxide (CO2)

Dry powder

Unsuitable extinguishing

media

For this substance/mixture no limitations of extinguishing

agents are given.

Specific hazards during fire-

fighting

Combustible.

Development of hazardous combustion gases or vapours

possible in the event of fire.

Fire may cause evolution of:

Hydrogen chloride gas

nitrogen oxides

nitrogen oxides

Hydrogen chloride gas

Hazardous combustion prod: :

ucts

No hazardous combustion products are known

Further information : Standard procedure for chemical fires.

Use extinguishing measures that are appropriate to local cir-

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023 2.1

cumstances and the surrounding environment.

Suppress (knock down) gases/vapours/mists with a water

spray jet.

(contamination risk)

Special protective equipment:

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

tive equipment and emer-

gency procedures

Personal precautions, protec- : Advice for non-emergency personnel:

Avoid inhalation of dusts.

Evacuate the danger area, observe emergency procedures,

consult an expert.

Advice for emergency responders: Protective equipment see section 8.

Environmental precautions Prevent product from entering drains.

Prevent further leakage or spillage if safe to do so.

If the product contaminates rivers and lakes or drains inform

respective authorities.

Methods and materials for

containment and cleaning up

Keep in suitable, closed containers for disposal.

Cover drains. Collect, bind, and pump off spills. Observe possible material restrictions (see sections 7 and 10).

Take up dry. Dispose of properly. Clean up affected area.

Avoid generation of dusts.

SECTION 7. HANDLING AND STORAGE

Technical measures Install appropriate equipment and wear appropriate personal

protective equipment (see "8. Exposure control/personal pro-

tection").

Local/Total ventilation Ensure adequate ventilation.

Advice on protection against

fire and explosion

Provide appropriate exhaust ventilation at places where dust

is formed.

Advice on safe handling Observe label precautions.

Avoid formation of respirable particles.

Do not breathe vapours/dust.

For personal protection see section 8.

Smoking, eating and drinking should be prohibited in the ap-

plication area.

Dispose of rinse water in accordance with local and national

regulations.

Keep container tightly closed in a dry and well-ventilated Conditions for safe storage

place.

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 11/15/2023

 2.1
 04/16/2024
 90MDGM302635
 Date of first issue: 02/13/2023

Observe label precautions.

Electrical installations / working materials must comply with

the technological safety standards.

Further information on stor-

age stability

No decomposition if stored and applied as directed.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
magnesium distearate	557-04-0	TWA (Inhal- able particu- late matter)	10 mg/m3	ACGIH
		TWA (Respirable particulate matter)	3 mg/m3	ACGIH

Engineering measures : Technical measures and appropriate working operations

should be given priority over the use of personal protective

equipment.

See section 7.1.

Personal protective equipment

Respiratory protection : required when dusts are generated.

Filter type : Filter P 3 (acc. to DIN 3181) for solid and liquid particles of

toxic and very toxic substances

Hand protection

Material : Nitrile rubber
Break through time : > 480 min
Glove thickness : 0.11 mm

Manufacturer : KCL 741 Dermatril® L

Remarks : The suitability for a specific workplace should be discussed

with the producers of the protective gloves.

Eye protection : Eye wash bottle with pure water

Tightly fitting safety goggles

Skin and body protection : Dust impervious protective suit

Choose body protection according to the amount and concentration of the dangerous substance at the work place.

Protective measures : The type of protective equipment must be selected according

to the concentration and amount of the dangerous substance

at the specific workplace.

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

Hygiene measures : Wash hands before breaks and at the end of workday.

Change contaminated clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : tablets

Colour : white

Odour : odourless

Odour Threshold : Not applicable

pH : No data available

Melting point/range : No data available

Boiling point/boiling range : No data available

Flash point : No data available

Evaporation rate : Not applicable

Flammability (solid, gas) : No data available

Self-ignition : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

soluble

Partition coefficient: n- : No data available

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

octanol/water

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not classified as explosive.

Oxidizing properties : none

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No decomposition if stored and applied as directed.

Chemical stability : The product is chemically stable under standard ambient con-

ditions (room temperature).

Possibility of hazardous reac- :

tions

Violent reactions possible with:

Strong oxidizing agents

Conditions to avoid : no information available

Incompatible materials : Not applicable

Hazardous decomposition

products

in the event of fire: See section 5.

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Remarks: No data available

Acute toxicity estimate: 1,102 mg/kg

Method: Calculation method

Remarks: absorption

Acute toxicity estimate: 1,098 mg/kg

Method: Calculation method

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Components:

cladribine:

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

Acute oral toxicity : Acute toxicity estimate (Rat): 50.1 mg/kg

Method: Expert judgement

magnesium distearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: (External MSDS)

Assessment: The substance or mixture has no acute oral tox-

icity

Skin corrosion/irritation

Not classified due to lack of data.

Product:

Remarks : No data available

Serious eye damage/eye irritation

Not classified due to lack of data.

Product:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified due to lack of data.

Respiratory sensitisation

Not classified due to lack of data.

Product:

Remarks : No data available

Germ cell mutagenicity

Suspected of causing genetic defects.

Product:

Genotoxicity in vitro : Remarks: No data available

Genotoxicity in vivo : Remarks: No data available

Germ cell mutagenicity -

Assessment

: Evidence of genetic defects.

Components:

cladribine:

Genotoxicity in vivo : Remarks: In vivo tests showed mutagenic effects

Germ cell mutagenicity -

Assessment

: In vitro tests showed mutagenic effects

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

Carcinogenicity

Not classified due to lack of data.

Components:

cladribine:

Remarks : No substantiated information from toxicological studies availa-

ble.

IARC No component of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No component of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Suspected of damaging fertility. Suspected of damaging the unborn child.

Product:

Reproductive toxicity - As-

sessment

: Evidence to impair fertility.

Evidence of harm to the unborn child.

Components:

cladribine:

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on sexual function and

fertility, based on animal experiments.

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified due to lack of data.

STOT - repeated exposure

Causes damage to organs through prolonged or repeated exposure.

Product:

Assessment : Mixture may cause damage to organs through prolonged or

repeated exposure.

Components:

cladribine:

Assessment : The substance or mixture is classified as specific target organ

toxicant, repeated exposure, category 1.

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

Repeated dose toxicity

Product:

Remarks : No data available

Components:

cladribine:

Species : Mouse
NOAEL : 15 mg/kg
Application Route : Oral
Exposure time : 26 Weeks

Target Organs : Kidney, thymus, Testes

Aspiration toxicity

Not classified due to lack of data.

Further information

Product:

Remarks : Physiologically active substance.

Remarks : Other dangerous properties can not be excluded.

Remarks : Therapeutically used substance.

Remarks : Handle in accordance with good industrial hygiene and safety

practice.

Remarks : Other dangerous properties can not be excluded.

Remarks : Handle in accordance with good industrial hygiene and safety

practice.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Product:

Toxicity to fish : Remarks: No data available

Toxicity to daphnia and other :

aquatic invertebrates Remarks: No data available

Toxicity to algae/aquatic

plants Remarks: No data available

Toxicity to fish (Chronic tox-

icity)

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

Remarks: No data available

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

ic toxicity)

Toxicity to microorganisms : Remarks: No data available

Components:

cladribine:

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia (water flea)): 233 mg/l

Exposure time: 48 h

Remarks: (External MSDS)

Persistence and degradability

No data available

Bioaccumulative potential

Components:

magnesium distearate:

Partition coefficient: n-

octanol/water

log Pow: 0.8

Method: OECD Test Guideline 107

Remarks: Bioaccumulation is not expected.

Mobility in soilNo data available

Other adverse effects

Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Pro-

tection of Stratospheric Ozone - CAA Section 602 Class I

Substances

Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Additional ecological infor-

mation

Discharge into the environment must be avoided.

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Do not contaminate ponds, waterways or ditches with chemi-

cal or used container.

Send to a licensed waste management company.

Waste material must be disposed of in accordance with the national and local regulations. Leave chemicals in original containers. No mixing with other waste. Handle uncleaned

containers like the product itself.

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

Contaminated packaging : Empty remaining contents.

Dispose of as unused product. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

Special precautions for user

Remarks : Not classified as dangerous in the meaning of transport regu-

lations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Acute toxicity (any route of exposure)

Germ cell mutagenicity Reproductive toxicity

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCMI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations

Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.

Pennsylvania Right To Know

2-hydroxypropyl-ß-cyclodextrin 128446-35-5 D-sorbitol 50-70-4 cladribine 4291-63-8

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

California Prop. 65

WARNING: This product can expose you to chemicals including cladribine, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

magnesium distearate 557-04-0

The components of this product are reported in the following inventories:

TCSI : On the inventory, or in compliance with the inventory

TSCA : Product contains substance(s) not listed on TSCA inventory.

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not

on the Canadian DSL nor NDSL.

cladribine

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023
2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

2-hydroxypropyl-ß-cyclodextrin

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

NZIoC : Not in compliance with the inventory

TECI: Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

Company internal Occupational Exposure Limit (MOEL)

cladribine (4291-63-8)

0.2 µg/m3

Short Term Exposure (15 min): 4

Factor

Pregnancy risk groups : D

Either there are no data for an assessment of damage to the embryo, or foetus or the currently available data are not suffi-

cient for classification in one of the other groups.

Further information

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

NFPA 704:

Health 1 0 Instability

Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response: EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI -Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ -Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Sub-

according to the OSHA Hazard Communication Standard



CLADRIBINE 10MG TABLETS

Version Revision Date: SDS Number: Date of last issue: 11/15/2023 2.1 04/16/2024 90MDGM302635 Date of first issue: 02/13/2023

stance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Revision Date : 04/16/2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / EN